David Irvine, MD
Family Medicine · Albany, ORNPI 1801960281
Payments from drug & device makers
Across 118 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$264
- Amgen$251
- Pfizer$236
- Lilly USA, LLC$164
- Novo Nordisk$135
- Novartis$107
- plus $811 from 20 others
What the payments were for
- Food & beverage$1,93198%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $264 |
| Amgen | 14 | $251 |
| Pfizer | 16 | $236 |
| Lilly USA, LLC | 10 | $164 |
| Novo Nordisk | 7 | $135 |
| Novartis | 7 | $107 |
| Edwards Lifesciences | 3 | $84 |
| AbbVie(2 entities) | 4 | $83 |
| Exact Sciences | 4 | $80 |
| Johnson & Johnson(2 entities) | 6 | $76 |
| GSK | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 5 | $62 |
| Merck | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Sanofi Pasteur Inc. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,967 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $634 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $184 |
| Prednisone | 49 | $179 |
| Cephalexin | 23 | $131 |
| Tizanidine Hcl | 20 | $110 |
| Levothyroxine Sodium | 11 | $102 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $92 |
| Amoxicillin | 13 | $75 |
| Azithromycin | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Albany
- Matthew BainAlbany$11K
- Daniel MosherAlbany$9K
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
- Patricia BuchananEugene$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.